

# Claus Belka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3011780/publications.pdf>

Version: 2024-02-01

245  
papers

6,755  
citations

94433

37  
h-index

95266

68  
g-index

254  
all docs

254  
docs citations

254  
times ranked

8504  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Novel Gene Signature-Based Model Predicts Biochemical Recurrence-Free Survival in Prostate Cancer Patients after Radical Prostatectomy. <i>Cancers</i> , 2020, 12, 1.	3.7	300
2	ESTRO-ACROP guideline –target delineation of glioblastomas–. <i>Radiotherapy and Oncology</i> , 2016, 118, 35-42.	0.6	286
3	Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. <i>Radiation Oncology</i> , 2019, 14, 141.	2.7	285
4	Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma. <i>JAMA Oncology</i> , 2018, 4, 483.	7.1	227
5	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 146, 223-229.	0.6	168
6	Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. <i>Immunological Reviews</i> , 2017, 280, 249-279.	6.0	155
7	Dying cell clearance and its impact on the outcome of tumor radiotherapy. <i>Frontiers in Oncology</i> , 2012, 2, 116.	2.8	152
8	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2014, 113, 317-323.	0.6	141
9	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2016, 121, 364-373.	0.6	130
10	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(+) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. <i>Clinical Cancer Research</i> , 2016, 22, 2639-2649.	7.0	127
11	European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. <i>Lancet Oncology</i> , The, 2022, 23, e21-e31.	10.7	117
12	Investigating CT to CBCT image registration for head and neck proton therapy as a tool for daily dose recalculation. <i>Medical Physics</i> , 2015, 42, 1354-1366.	3.0	115
13	Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. <i>Radiotherapy and Oncology</i> , 2017, 124, 526-532.	0.6	107
14	Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review. <i>Radiation Oncology</i> , 2020, 15, 214.	2.7	103
15	ScatterNet: A convolutional neural network for cone-beam CT intensity correction. <i>Medical Physics</i> , 2018, 45, 4916-4926.	3.0	101
16	External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2018, 25, 754-767.	1.5	95
17	Investigating deformable image registration and scatter correction for CBCT-based dose calculation in adaptive IMPT. <i>Medical Physics</i> , 2016, 43, 5635-5646.	3.0	92
18	Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells. <i>Oncotimmunology</i> , 2019, 8, e1523097.	4.6	91

#	ARTICLE	IF	CITATIONS
19	Comparison of proton therapy treatment planning for head tumors with a pencil beam algorithm on dual and single energy CT images. <i>Medical Physics</i> , 2016, 43, 495-504.	3.0	89
20	Current status and perspectives of interventional clinical trials for glioblastoma – analysis of ClinicalTrials.gov. <i>Radiation Oncology</i> , 2017, 12, 1.	2.7	87
21	First Clinical Results for PSMA-Targeted $\alpha$ -Therapy Using $^{225}\text{Ac}$ -PSMA-I&T in Advanced-mCRPC Patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, 669-674.	5.0	87
22	Comparing cone-beam CT intensity correction methods for dose recalculation in adaptive intensity-modulated photon and proton therapy for head and neck cancer. <i>Acta Oncologica</i> , 2015, 54, 1651-1657.	1.8	83
23	Current status and recent advances in reirradiation of glioblastoma. <i>Radiation Oncology</i> , 2021, 16, 36.	2.7	80
24	A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection. <i>Clinical Cancer Research</i> , 2019, 25, 1505-1516.	7.0	67
25	Does deep inspiration breath-hold prolong life? Individual risk estimates of ischaemic heart disease after breast cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 131, 202-207.	0.6	65
26	Left-sided breast cancer and risks of secondary lung cancer and ischemic heart disease. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 196-205.	2.0	63
27	Outcome After PSMA PET/CT-Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 227-233.	5.0	61
28	Progressive resistance training in cachectic head and neck cancer patients undergoing radiotherapy: a randomized controlled pilot feasibility trial. <i>Radiation Oncology</i> , 2018, 13, 215.	2.7	55
29	Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. <i>Radiation Oncology</i> , 2018, 13, 37.	2.7	54
30	Feasibility of automated proton therapy plan adaptation for head and neck tumors using cone beam CT images. <i>Radiation Oncology</i> , 2016, 11, 64.	2.7	52
31	Combined intracavitary and interstitial brachytherapy of cervical cancer using the novel hybrid applicator Venezia: Clinical feasibility and initial results. <i>Brachytherapy</i> , 2018, 17, 775-781.	0.5	48
32	Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients. <i>Theranostics</i> , 2021, 11, 5061-5076.	10.0	48
33	Analysis of clonogenic growth in vitro. <i>Nature Protocols</i> , 2021, 16, 4963-4991.	12.0	45
34	Impact of $^{68}\text{Ga}$ -PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 963-970.	5.0	44
35	ESTRO ACROP guideline for target volume delineation of skull base tumors. <i>Radiotherapy and Oncology</i> , 2021, 156, 80-94.	0.6	41
36	Release of monocyte migration signals by breast cancer cell lines after ablative and fractionated $\beta$ -irradiation. <i>Radiation Oncology</i> , 2014, 9, 85.	2.7	40

#	ARTICLE	IF	CITATIONS
37	HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas. <i>Cancer Letters</i> , 2015, 365, 211-222.	7.2	40
38	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 631-640.	0.8	40
39	Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1-3 cerebral metastases. <i>Radiation Oncology</i> , 2014, 9, 105.	2.7	39
40	Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis. <i>Radiation Oncology</i> , 2017, 12, 2.	2.7	37
41	Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DTK/ROG analysis. <i>Radiotherapy and Oncology</i> , 2018, 127, 121-127.	0.6	37
42	Feasibility and Early Clinical Experience of Online Adaptive MR-Guided Radiotherapy of Liver Tumors. <i>Cancers</i> , 2021, 13, 1523.	3.7	37
43	Radiotherapy of oligometastatic prostate cancer: a systematic review. <i>Radiation Oncology</i> , 2021, 16, 50.	2.7	37
44	ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology. <i>Radiotherapy and Oncology</i> , 2021, 159, 146-154.	0.6	37
45	Single isocenter stereotactic radiosurgery for patients with multiple brain metastases: dosimetric comparison of VMAT and a dedicated DCAT planning tool. <i>Radiation Oncology</i> , 2019, 14, 103.	2.7	36
46	ESTRO ACROP guidelines for target volume definition in pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2021, 154, 60-69.	0.6	36
47	Comparison and Limitations of DVH-Based NTCP Models Derived From 3D-CRT and IMRT Data for Prediction of Gastrointestinal Toxicities in Prostate Cancer Patients by Using Propensity Score Matched Pair Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 435-443.	0.8	35
48	A 4-miRNA signature predicts the therapeutic outcome of glioblastoma. <i>Oncotarget</i> , 2016, 7, 45764-45775.	1.8	35
49	Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. <i>Radiation Oncology</i> , 2017, 12, 176.	2.7	34
50	PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. <i>Radiation Oncology</i> , 2018, 13, 90.	2.7	34
51	Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma. <i>Radiotherapy and Oncology</i> , 2019, 138, 99-105.	0.6	34
52	Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. <i>European Urology Focus</i> , 2021, 7, 309-316.	3.1	34
53	Evaluation of proton and photon dose distributions recalculated on 2D and 3D Unet-generated pseudoCTs from T1-weighted MR head scans. <i>Acta Oncologica</i> , 2019, 58, 1429-1434.	1.8	33
54	On the analysis of clonogenic survival data: Statistical alternatives to the linear-quadratic model. <i>Radiation Oncology</i> , 2016, 11, 11.	2.7	32

#	ARTICLE	IF	CITATIONS
55	Volumetric and actuarial analysis of brain necrosis in proton therapy using a novel mixture cure model. <i>Radiotherapy and Oncology</i> , 2020, 142, 154-161.	0.6	30
56	Adjuvant radiotherapy after breast conserving surgery – A comparative effectiveness research study. <i>Radiotherapy and Oncology</i> , 2015, 114, 28-34.	0.6	29
57	Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. <i>Radiation Oncology</i> , 2020, 15, 167.	2.7	29
58	Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?. <i>Oncotarget</i> , 2016, 7, 2313-2328.	1.8	29
59	Excellent local control and survival after postoperative or definitive radiation therapy for sarcomas of the head and neck. <i>Radiation Oncology</i> , 2015, 10, 140.	2.7	28
60	Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 591-599.	2.9	28
61	Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group – Personalized Radiotherapy in Head and Neck Cancer. <i>Radiation Oncology</i> , 2020, 15, 7.	2.7	28
62	Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. <i>Radiation Oncology</i> , 2020, 15, 5.	2.7	28
63	Pre-clinical heterotopic intrathoracic heart xenotransplantation: a possibly useful clinical technique. <i>Xenotransplantation</i> , 2015, 22, 427-442.	2.8	27
64	Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference. <i>Journal of Neurology</i> , 2017, 264, 350-358.	3.6	27
65	Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease. <i>Radiation Oncology</i> , 2018, 13, 100.	2.7	27
66	Towards a novel small animal proton irradiation platform: the SIRMIO project. <i>Acta Oncologica</i> , 2019, 58, 1470-1475.	1.8	27
67	Current status and recent advances in resection cavity irradiation of brain metastases. <i>Radiation Oncology</i> , 2021, 16, 73.	2.7	27
68	Shorter treatment times reduce the impact of intra-fractional motion. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 664-674.	2.0	26
69	Stereotactic radiosurgery combined with targeted/ immunotherapy in patients with melanoma brain metastasis. <i>Radiation Oncology</i> , 2020, 15, 37.	2.7	26
70	Patient positioning and immobilization procedures for hybrid MR-Linac systems. <i>Radiation Oncology</i> , 2021, 16, 183.	2.7	26
71	PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC – current state and future directions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3975-3989.	6.4	25
72	Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients. <i>Investigational New Drugs</i> , 2021, 39, 1189-1196.	2.6	25

#	ARTICLE	IF	CITATIONS
73	Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort. <i>Radiation Oncology</i> , 2014, 9, 128.	2.7	24
74	A comparative assessment of prostate positioning guided by three-dimensional ultrasound and cone beam CT. <i>Radiation Oncology</i> , 2015, 10, 82.	2.7	24
75	A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer. <i>Oncotarget</i> , 2016, 7, 43199-43219.	1.8	24
76	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 125-131.	0.6	24
77	Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck – clinical results from the cohort of the clinical cooperation group “Personalized Radiotherapy in Head and Neck Cancer”. <i>Radiation Oncology</i> , 2018, 13, 123.	2.7	24
78	Novel rotatable tabletop for total-body irradiation using a linac-based VMAT technique. <i>Radiation Oncology</i> , 2019, 14, 244.	2.7	24
79	Characterization of immune landscape in papillary thyroid cancer reveals distinct tumor immunogenicity and implications for immunotherapy. <i>Oncolimmunology</i> , 2021, 10, e1964189.	4.6	24
80	Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate. <i>Radiation Oncology</i> , 2022, 17, 53.	2.7	24
81	Outcome and toxicity profile of salvage low-dose-rate iodine-125 stereotactic brachytherapy in recurrent high-grade gliomas. <i>Acta Neurochirurgica</i> , 2015, 157, 1757-1764.	1.7	23
82	Treatment Response and Prophylactic Cranial Irradiation Are Prognostic Factors in a Real-life Limited-disease Small-cell Lung Cancer Patient Cohort Comprehensively Staged With Cranial Magnetic Resonance Imaging. <i>Clinical Lung Cancer</i> , 2017, 18, e243-e249.	2.6	23
83	Neoadjuvant radiotherapy followed by mastectomy and immediate breast reconstruction. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 324-331.	2.0	23
84	Clinical outcome of elderly patients (>70 years) with esophageal cancer undergoing definitive or neoadjuvant radio(chemo)therapy: a retrospective single center analysis. <i>Radiation Oncology</i> , 2018, 13, 93.	2.7	23
85	Margin reduction in radiotherapy for glioblastoma through 18F-fluoroethyltyrosine PET? – A recurrence pattern analysis. <i>Radiotherapy and Oncology</i> , 2020, 145, 49-55.	0.6	23
86	Dosimetric comparison of MR-linac-based IMRT and conventional VMAT treatment plans for prostate cancer. <i>Radiation Oncology</i> , 2021, 16, 133.	2.7	23
87	Early senescence and production of senescence-associated cytokines are major determinants of radioresistance in head-and-neck squamous cell carcinoma. <i>Cell Death and Disease</i> , 2021, 12, 1162.	6.3	23
88	Comparison of prostate positioning guided by three-dimensional transperineal ultrasound and cone beam CT. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 221-228.	2.0	22
89	Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 107-115.	2.0	22
90	Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [18F]FMISO PET/CT. <i>Radiotherapy and Oncology</i> , 2022, 171, 30-36.	0.6	22

#	ARTICLE	IF	CITATIONS
91	18F-FET PET prior to recurrent high-grade glioma re-irradiation—additional prognostic value of dynamic time-to-peak analysis and early static summation images?. <i>Journal of Neuro-Oncology</i> , 2017, 132, 277-286.	2.9	21
92	Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance. <i>Cancer Letters</i> , 2017, 386, 87-99.	7.2	21
93	A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC). <i>Molecular Oncology</i> , 2018, 12, 2085-2101.	4.6	21
94	Neoadjuvant Chemoradiation Combined with Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer. <i>Cancers</i> , 2021, 13, 1279.	3.7	21
95	Prophylactic cranial irradiation in small-cell lung cancer: update on patient selection, efficacy and outcomes. <i>Lung Cancer: Targets and Therapy</i> , 2018, Volume 9, 49-55.	2.7	20
96	Dose variability in different lymph node levels during locoregional breast cancer irradiation: the impact of deep-inspiration breath hold. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 13-20.	2.0	20
97	Real-time 4DMRI-based internal target volume definition for moving lung tumors. <i>Medical Physics</i> , 2020, 47, 1431-1442.	3.0	20
98	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. <i>BMC Cancer</i> , 2020, 20, 362.	2.6	20
99	Temozolomide during radiotherapy of glioblastoma multiforme. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 890-896.	2.0	19
100	Dose-guided patient positioning in proton radiotherapy using multicriteria-optimization. <i>Zeitschrift Fur Medizinische Physik</i> , 2019, 29, 216-228.	1.5	19
101	Distant metastasis time to event analysis with CNNs in independent head and neck cancer cohorts. <i>Scientific Reports</i> , 2021, 11, 6418.	3.3	19
102	Impact of MLC properties and IMRT technique in meningioma and head-and-neck treatments. <i>Radiation Oncology</i> , 2015, 10, 184.	2.7	18
103	Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting. <i>Cancers</i> , 2021, 13, 1613.	3.7	18
104	Heart sparing radiotherapy in breast cancer: the importance of baseline cardiac risks. <i>Radiation Oncology</i> , 2020, 15, 117.	2.7	18
105	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. <i>Radiotherapy and Oncology</i> , 2018, 127, 27-35.	0.6	17
106	Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment. <i>Anticancer Research</i> , 2019, 39, 5077-5081.	1.1	17
107	State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours—a German radiation oncology survey. <i>European Journal of Cancer</i> , 2019, 108, 50-54.	2.8	17
108	Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer. <i>Radiation Oncology</i> , 2020, 15, 148.	2.7	17

#	ARTICLE	IF	CITATIONS
109	Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer. Radiation Oncology, 2021, 16, 125.	2.7	17
110	Risk and timing of biochemical recurrence in pT3aNO/Nx prostate cancer with positive surgical margin â€“ A multicenter study. Radiotherapy and Oncology, 2015, 116, 119-124.	0.6	16
111	Recent Developments in Radiation Oncology: An Overview of Individualised Treatment Strategies in Breast Cancer. Breast Care, 2018, 13, 285-291.	1.4	16
112	Recurrence pattern analysis after [68Ga]-DOTATATE-PET/CT -planned radiotherapy of high-grade meningiomas. Radiation Oncology, 2018, 13, 110.	2.7	16
113	Feasibility of 4DCBCT-based proton dose calculation: An ex vivo porcine lung phantom study. Zeitschrift Fur Medizinische Physik, 2019, 29, 249-261.	1.5	16
114	RADIANCE â€“ Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clinical and Translational Radiation Oncology, 2020, 23, 43-49.	1.7	16
115	Normal tissue complication models for clinically relevant acute esophagitis (â‰¥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid). Radiation Oncology, 2015, 10, 121.	2.7	15
116	Multi-criterial patient positioning based on dose recalculation on scatter-corrected CBCT images. Radiotherapy and Oncology, 2017, 125, 464-469.	0.6	15
117	Prefraction displacement and intrafraction drift of the prostate due to perineal ultrasound probe pressure. Strahlentherapie Und Onkologie, 2017, 193, 459-465.	2.0	15
118	Porcine lung phantom-based validation of estimated 4D-MRI using orthogonal cine imaging for low-field MR-Linacs. Physics in Medicine and Biology, 2021, 66, 055006.	3.0	15
119	MR-guided SBRT boost for patients with locally advanced or recurrent gynecological cancers ineligible for brachytherapy: feasibility and early clinical experience. Radiation Oncology, 2022, 17, 8.	2.7	15
120	Feasibility study on image guided patient positioning for stereotactic body radiation therapy of liver malignancies guided by liver motion. Radiation Oncology, 2016, 11, 88.	2.7	14
121	Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair. International Journal of Cancer, 2016, 139, 467-479.	5.1	14
122	Radiotherapy of spinal cord gliomas. Strahlentherapie Und Onkologie, 2016, 192, 139-145.	2.0	14
123	Three-dimensional surface imaging in breast cancer: a new tool for clinical studies?. Radiation Oncology, 2020, 15, 52.	2.7	14
124	Offline and online LSTM networks for respiratory motion prediction in MR-guided radiotherapy. Physics in Medicine and Biology, 2022, 67, 095006.	3.0	14
125	Prognostic role of patient gender in limited-disease small-cell lung cancer treated with chemoradiotherapy. Strahlentherapie Und Onkologie, 2017, 193, 150-155.	2.0	13
126	Trends in use and outcome of postoperative radiotherapy following mastectomy: A population-based study. Radiotherapy and Oncology, 2017, 122, 2-10.	0.6	13



#	ARTICLE	IF	CITATIONS
127	Impact of surface-guided positioning on the use of portal imaging and initial set-up duration in breast cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 964-971.	2.0	13
128	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2328-2338.	6.4	13
129	Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1417-1428.	6.4	13
130	Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1038-1052.	7.0	13
131	Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases. <i>Radiation Oncology</i> , 2018, 13, 25.	2.7	12
132	Inhibition of HSP90 as a Strategy to Radiosensitize Glioblastoma: Targeting the DNA Damage Response and Beyond. <i>Frontiers in Oncology</i> , 2021, 11, 612354.	2.8	12
133	Dosimetric impact of deep learning-based CT auto-segmentation on radiation therapy treatment planning for prostate cancer. <i>Radiation Oncology</i> , 2022, 17, 21.	2.7	12
134	Stereoscopic X-ray imaging, cone beam CT, and couch positioning in stereotactic radiotherapy of intracranial tumors: preliminary results from a cross-modality pilot installation. <i>Radiation Oncology</i> , 2016, 11, 158.	2.7	11
135	Medulloblastoma in adults. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 225-234.	2.0	11
136	Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1581-1589.	2.5	11
137	How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2103-2109.	6.4	11
138	SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine. <i>Radiation Oncology</i> , 2020, 15, 165.	2.7	11
139	Hypofractionated Radiotherapy for Anaplastic Thyroid Cancer: Systematic Review and Pooled Analysis. <i>Cancers</i> , 2020, 12, 2506.	3.7	11
140	Simultaneous stereotactic radiosurgery of multiple brain metastases using single-isocenter dynamic conformal arc therapy: a prospective monocentric registry trial. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 601-613.	2.0	11
141	Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 640467.	2.8	11
142	Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma. <i>Radiation Oncology</i> , 2021, 16, 86.	2.7	11
143	Multifocal high-grade glioma radiotherapy safety and efficacy. <i>Radiation Oncology</i> , 2021, 16, 165.	2.7	11
144	Dose optimization of total or partial skin electron irradiation by thermoluminescent dosimetry. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 444-453.	2.0	10

#	ARTICLE	IF	CITATIONS
145	Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center Analysis. <i>Cancers</i> , 2020, 12, 3035.	3.7	10
146	The dosimetric impact of replacing the TG-43 algorithm by model based dose calculation for liver brachytherapy. <i>Radiation Oncology</i> , 2020, 15, 60.	2.7	10
147	Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 801-810.	2.8	10
148	PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook. <i>Frontiers in Oncology</i> , 2021, 11, 774017.	2.8	10
149	Stereotactic radiotherapy of intrapulmonary lesions: comparison of different dose calculation algorithms for Oncentra MasterPlan®. <i>Radiation Oncology</i> , 2015, 10, 51.	2.7	9
150	Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis. <i>Radiation Oncology</i> , 2019, 14, 163.	2.7	9
151	Comparison of planned dose on different CT image sets to four-dimensional Monte Carlo dose recalculation using the patient's actual breathing trace for lung stereotactic body radiation therapy. <i>Medical Physics</i> , 2019, 46, 3268-3277.	3.0	9
152	Deformable image registration of the treatment planning CT with proton radiographies in perspective of adaptive proton therapy. <i>Physics in Medicine and Biology</i> , 2021, 66, 045008.	3.0	9
153	MLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF. <i>Cell Death and Differentiation</i> , 2021, 28, 3235-3250.	11.2	9
154	MR-guided radiotherapy in node-positive non-small cell lung cancer and severely limited pulmonary reserve: a report proposing a new clinical pathway for the management of high-risk patients. <i>Radiation Oncology</i> , 2022, 17, 43.	2.7	9
155	Establishment and Validation of an Individualized Cell Cycle Process-Related Gene Signature to Predict Cancer-Specific Survival in Patients with Bladder Cancer. <i>Cancers</i> , 2020, 12, 1146.	3.7	8
156	Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study. <i>Radiation Oncology</i> , 2020, 15, 19.	2.7	8
157	Measurement-based range evaluation for quality assurance of CBCT-based dose calculations in adaptive proton therapy. <i>Medical Physics</i> , 2021, 48, 4148-4159.	3.0	8
158	HDR Brachytherapy and SBRT as Bridging Therapy to Liver Transplantation in HCC Patients: A Single-Center Experience. <i>Frontiers in Oncology</i> , 2021, 11, 717792.	2.8	8
159	Longitudinal [18F]GE-180 PET Imaging Facilitates In Vivo Monitoring of TSPO Expression in the GL261 Glioblastoma Mouse Model. <i>Biomedicines</i> , 2022, 10, 738.	3.2	8
160	Iodine-125 brachytherapy as upfront and salvage treatment for brain metastases. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 780-788.	2.0	7
161	Use of diffusion-weighted MRI to modify radiosurgery planning in brain metastases may reduce local recurrence. <i>Journal of Neuro-Oncology</i> , 2017, 131, 549-554.	2.9	7
162	Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 289-296.	2.0	7

#	ARTICLE	IF	CITATIONS
163	Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation. PLoS ONE, 2019, 14, e0216111.	2.5	7
164	Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. JNCI Cancer Spectrum, 2020, 4, pkz060.	2.9	7
165	Outcome After <sup>68</sup> Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis. Cancers, 2020, 12, 3395.	3.7	7
166	Anthropomorphic lung phantom based validation of in-room proton therapy 4D-CBCT image correction for dose calculation. Zeitschrift Fur Medizinische Physik, 2020, 32, 74-74.	1.5	7
167	Modeling RBE-weighted dose variations in irregularly moving abdominal targets treated with carbon ion beams. Medical Physics, 2020, 47, 2768-2778.	3.0	7
168	Patient-specific CT calibration based on ion radiography for different detector configurations in <sup>1</sup> H, <sup>4</sup> He and <sup>12</sup> C ion pencil beam scanning. Physics in Medicine and Biology, 2020, 65, 245014.	3.0	7
169	Impact of a low FODMAP diet on the amount of rectal gas and rectal volume during radiotherapy in patients with prostate cancer – a prospective pilot study. Radiation Oncology, 2020, 15, 27.	2.7	7
170	PSMA-positive nodal recurrence in prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 637-646.	2.0	7
171	Risk of biochemical recurrence and timing of radiotherapy in pT3a N0 prostate cancer with positive surgical margin. Strahlentherapie Und Onkologie, 2016, 192, 440-448.	2.0	6
172	Nodal Clearance Rate and Long-Term Efficacy of Individualized Sentinel Node-Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 263-271.	0.8	6
173	Stereotactic body radiotherapy in patients with hepatocellular carcinoma in a multimodal treatment setting. Strahlentherapie Und Onkologie, 2020, 196, 334-348.	2.0	6
174	Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC) – a German radiation oncology survey. Translational Lung Cancer Research, 2020, 9, 288-293.	2.8	6
175	Magnetic resonance-guided radiation therapy: the beginning of a new era. Radiation Oncology, 2020, 15, 163.	2.7	6
176	Validation of proton dose calculation on scatter corrected 4D cone beam computed tomography using a porcine lung phantom. Physics in Medicine and Biology, 2021, 66, 175022.	3.0	6
177	Forging a Path for Metformin Use in Inoperable Locally Advanced Non-Small Cell Lung Cancer. JAMA Oncology, 2021, 7, 1341.	7.1	6
178	Interstitial High-Dose-Rate Brachytherapy of Liver Metastases in Oligometastatic Patients. Cancers, 2021, 13, 6250.	3.7	6
179	Timing of Failure in Limited Disease (Stage I-III) Small-Cell Lung Cancer Patients Treated with Chemoradiotherapy: A Retrospective Analysis. Tumori, 2013, 99, 656-660.	1.1	5
180	Practical implications for the quality assurance of modulated radiation therapy techniques using point detector arrays. Journal of Applied Clinical Medical Physics, 2017, 18, 20-31.	1.9	5

#	ARTICLE	IF	CITATIONS
181	Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate. <i>European Journal of Cancer</i> , 2018, 95, 109-111.	2.8	5
182	Neoadjuvant chemoradiation for esophageal cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 435-443.	2.0	5
183	Clinical workflow optimization to improve 4DCT reconstruction for Toshiba Aquilion CT scanners. <i>Zeitschrift Fur Medizinische Physik</i> , 2018, 28, 88-95.	1.5	5
184	Optimization of Phase Space files from clinical linear accelerators. <i>Physica Medica</i> , 2019, 64, 54-68.	0.7	5
185	Dosimetric impact of intrafraction motion on boosts on intraprostatic lesions: a simulation based on actual motion data from real time ultrasound tracking. <i>Radiation Oncology</i> , 2019, 14, 81.	2.7	5
186	Priming of Anti-tumor Immune Mechanisms by Radiotherapy Is Augmented by Inhibition of Heat Shock Protein 90. <i>Frontiers in Oncology</i> , 2020, 10, 1668.	2.8	5
187	Maximum standardized uptake value of primary tumor (SUV <sub>max_PT</sub> ) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 541-548.	2.8	5
188	Radiotherapy in oncological emergencies: fast-track treatment planning. <i>Radiation Oncology</i> , 2020, 15, 215.	2.7	5
189	Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas. <i>Radiation Oncology</i> , 2020, 15, 275.	2.7	5
190	Variance-based sensitivity analysis for uncertainties in proton therapy: A framework to assess the effect of simultaneous uncertainties in range, positioning, and RBE model predictions on RBE-weighted dose distributions. <i>Medical Physics</i> , 2021, 48, 805-818.	3.0	5
191	Risk Stratification Using 18F-FDG PET/CT and Artificial Neural Networks in Head and Neck Cancer Patients Undergoing Radiotherapy. <i>Diagnostics</i> , 2021, 11, 1581.	2.6	5
192	Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition. <i>Investigational New Drugs</i> , 2021, , 1.	2.6	5
193	A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa. <i>Frontiers in Oncology</i> , 2021, 11, 723536.	2.8	5
194	Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1407-1416.	6.4	5
195	Combining inter-observer variability, range and setup uncertainty in a variance-based sensitivity analysis for proton therapy. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 20, 117-120.	2.9	5
196	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2022, 167, 300-307.	0.6	5
197	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC – Hypothesis generation on a multicentre cohort of the DKTK-ROG. <i>Radiotherapy and Oncology</i> , 2022, 169, 8-14.	0.6	5
198	Single-isocenter stereotactic radiosurgery for multiple brain metastases: Impact of patient misalignments on target coverage in non-coplanar treatments. <i>Zeitschrift Fur Medizinische Physik</i> , 2022, 32, 296-311.	1.5	5

#	ARTICLE	IF	CITATIONS
199	External Validation of a Survival Score for Limited-Stage Small Cell Lung Cancer Patients Treated with Chemoradiotherapy. Lung, 2020, 198, 201-206.	3.3	4
200	Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy. Anticancer Research, 2020, 40, 2319-2322.	1.1	4
201	Mammary Chain Irradiation in Left-Sided Breast Cancer: Can We Reduce the Risk of Secondary Cancer and Ischaemic Heart Disease with Modern Intensity-Modulated Radiotherapy Techniques?. Breast Care, 2021, 16, 358-367.	1.4	4
202	Radiation to the Primary Tumor in Metastatic Anaplastic Thyroid Cancer. In Vivo, 2021, 35, 461-465.	1.3	4
203	ESTRO ACROP guidelines for the delineation of lymph nodal areas in upper gastrointestinal malignancies. Radiotherapy and Oncology, 2021, 164, 92-97.	0.6	4
204	Distress in hospitalized cancer patients: Associations with personality traits, clinical and psychosocial characteristics. Psycho-Oncology, 2022, 31, 770-778.	2.3	4
205	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. Radiotherapy and Oncology, 2022, 171, 91-100.	0.6	4
206	Intra-fraction motion of the prostate is not increased by patient couch shifts. Radiation Oncology, 2016, 11, 49.	2.7	3
207	Prophylactic Cranial Irradiation for Patients with Small Cell Lung Cancer in Germany: Pattern of Care Survey. Anticancer Research, 2018, 38, 5261-5265.	1.1	3
208	Radiation necrosis after a combination of external beam radiotherapy and iodine-125 brachytherapy in gliomas. Radiation Oncology, 2021, 16, 40.	2.7	3
209	Accounting for prompt gamma emission and detection for range verification in proton therapy treatment planning. Physics in Medicine and Biology, 2021, 66, 055005.	3.0	3
210	Patient-Reported and Oncological Outcomes of Salvage Therapies for PSMA-Positive Nodal Recurrent Prostate Cancer: Real-Life Experiences and Implications for Future Trial Design. Frontiers in Oncology, 2021, 11, 708595.	2.8	3
211	A Privacy-Preserving Log-Rank Test for the Kaplan-Meier Estimator With Secure Multiparty Computation: Algorithm Development and Validation. JMIR Medical Informatics, 2021, 9, e22158.	2.6	3
212	Optimizing the Analytical Value of Oncology-Related Data Based on an In-Memory Analysis Layer: Development and Assessment of the Munich Online Comprehensive Cancer Analysis Platform. Journal of Medical Internet Research, 2020, 22, e16533.	4.3	3
213	Novel modified patient immobilisation device with an integrated coil support system for MR-guided online adaptive radiotherapy in the management of brain and head-and-neck tumours. Technical Innovations and Patient Support in Radiation Oncology, 2021, 20, 35-40.	1.9	3
214	Evaluation of an anthropomorphic ion chamber and 3D gel dosimetry head phantom at a 0.35 T MR-linac using separate 1.5 T MR-scanners for gel readout. Zeitschrift Fur Medizinische Physik, 2022, , .	1.5	3
215	Radiotherapy in oligometastatic prostate cancerâ€”a pattern of care survey among members of the German Society for Radiation Oncology (DEGRO). Strahlentherapie Und Onkologie, 2022, 198, 727-734.	2.0	3
216	Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy. Radiation Oncology, 2022, 17, 79.	2.7	3

#	ARTICLE	IF	CITATIONS
217	Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort. <i>Journal of Cancer</i> , 2016, 7, 2012-2017.	2.5	2
218	A 2D-3D Deformable Image Registration Framework for Proton Radiographies in Adaptive Radiation Therapy. , 2019, , .		2
219	The ProMotion LMU dataset, prostate intra-fraction motion recorded by transperineal ultrasound. <i>Scientific Data</i> , 2019, 6, 269.	5.3	2
220	Tumor microenvironment characterization in head and neck squamous carcinoma reveals distinct genomic alterations and clinical outcomes. <i>Clinical and Translational Medicine</i> , 2020, 10, e187.	4.0	2
221	Clinical Outcome and Toxicity in the Treatment of Anaplastic Thyroid Cancer in Elderly Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 3231.	2.4	2
222	Feasibility of hypofractionated radiotherapy in inoperable node-positive NSCLC patients with poor prognostic factors and limited pulmonary reserve: a prospective observational study. <i>Acta Oncologica</i> , 2021, 60, 1074-1078.	1.8	2
223	Multimodal therapy of cavernous sinus meningioma: impact of surgery and 68Ga-DOTATATE PET-guided radiation therapy on tumor control and functional outcome. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab114.	0.7	2
224	Dosimetric impact of geometric distortions in an MRI-only proton therapy workflow for lung, liver and pancreas. <i>Zeitschrift Fur Medizinische Physik</i> , 2020, , .	1.5	2
225	<sup>18</sup> F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1208-1214.	5.0	2
226	Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. <i>Journal of Neuro-Oncology</i> , 2019, 144, 501-509.	2.9	1
227	Multimodal “synergistic” treatment based on tumour immunological contexture for advanced non-driver non-small cell lung cancer: A myth or reality?. <i>European Journal of Cancer Care</i> , 2020, 29, e13291.	1.5	1
228	[F18] FDG-PET/CT for manual or semiautomated GTV delineation of the primary tumor for radiation therapy planning in patients with esophageal cancer: is it useful?. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 780-790.	2.0	1
229	X-change symposium: status and future of modern radiation oncology “from technology to biology. <i>Radiation Oncology</i> , 2021, 16, 27.	2.7	1
230	Validation of the collapsed cone algorithm for HDR liver brachytherapy against Monte Carlo simulations. <i>Brachytherapy</i> , 2021, 20, 936-947.	0.5	1
231	The impact of residual metabolic primary tumor volume after completion of thoracic irradiation in patients with inoperable stage III NSCLC.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9049-9049.	1.6	1
232	Pooled analysis on image-guided moderately hypofractionated thoracic irradiation in inoperable node-positive/recurrent patients with non-small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve. <i>Cancer</i> , 2022, 128, 2358-2366.	4.1	1
233	Prognostic impact of inflammatory profiling during and after multimodal treatment for stage III NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20559-e20559.	1.6	0
234	Association of planning target volume with disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20557-e20557.	1.6	0

#	ARTICLE	IF	CITATIONS
235	Longitudinal analysis of dynamic changes of T-lymphocytes during multimodal treatment of patients with inoperable stage III NSCLC.. Journal of Clinical Oncology, 2021, 39, e20503-e20503.	1.6	0
236	Differential role of residual metabolic tumor volume in patients with inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.. Journal of Clinical Oncology, 2021, 39, e20558-e20558.	1.6	0
237	Retransplantation with Stem Cells from Mismatched Related Donors after Graft Rejection in Pediatric Patients.. Blood, 2006, 108, 2955-2955.	1.4	0
238	4-miRNA signature combined with MGMT methylation status in glioblastoma: A multicentric retrospective biomarker analysis with accompanying prospective cohort study.. Journal of Clinical Oncology, 2020, 38, 2517-2517.	1.6	0
239	Dynamic changes of lymphocyte subsets during multimodal treatment of patients with inoperable stage III NSCLC.. Journal of Clinical Oncology, 2020, 38, e21011-e21011.	1.6	0
240	Propensity score matching analysis of patients with inoperable stage III NSCLC treated with chemoradio- vs. chemoradioimmunotherapy.. Journal of Clinical Oncology, 2020, 38, e21087-e21087.	1.6	0
241	Primary radiation therapy in stage I/II indolent orbital lymphoma â€“ a comprehensive retrospective recurrence and toxicity analysis. European Journal of Haematology, 2022, , .	2.2	0
242	Treatment patterns and prognosis in inoperable stage III NSCLC after concurrent chemoradiotherapy with or without immune checkpoint inhibition: Historical overview.. Journal of Clinical Oncology, 2022, 40, e20578-e20578.	1.6	0
243	Propensity-matched analysis of concurrent/sequential versus sequential immune checkpoint inhibition in inoperable stage III NSCLC patients treated with chemoradiotherapy.. Journal of Clinical Oncology, 2022, 40, e20589-e20589.	1.6	0
244	Absence of CD4 <sup>+</sup> and CD8 <sup>+</sup> T cell expansion after primary multimodal treatment predicts early progression in inoperable stage III NSCLC.. Journal of Clinical Oncology, 2022, 40, e20590-e20590.	1.6	0
245	Pattern of failure in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy with/without immune checkpoint inhibition.. Journal of Clinical Oncology, 2022, 40, e20570-e20570.	1.6	0